JP2019500026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500026A5 JP2019500026A5 JP2018526167A JP2018526167A JP2019500026A5 JP 2019500026 A5 JP2019500026 A5 JP 2019500026A5 JP 2018526167 A JP2018526167 A JP 2018526167A JP 2018526167 A JP2018526167 A JP 2018526167A JP 2019500026 A5 JP2019500026 A5 JP 2019500026A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- attenuated gram
- recombinant attenuated
- negative
- negative strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15195490.6 | 2015-11-19 | ||
| EP15195490 | 2015-11-19 | ||
| PCT/EP2016/078084 WO2017085233A1 (en) | 2015-11-19 | 2016-11-17 | Virulence attenuated bacteria for treatment of malignant solid tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500026A JP2019500026A (ja) | 2019-01-10 |
| JP2019500026A5 true JP2019500026A5 (https=) | 2021-12-16 |
| JP7060503B2 JP7060503B2 (ja) | 2022-04-26 |
Family
ID=54697464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526167A Active JP7060503B2 (ja) | 2015-11-19 | 2016-11-17 | 悪性固形腫瘍の治療のための弱毒化細菌 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11166987B2 (https=) |
| EP (2) | EP3377094B1 (https=) |
| JP (1) | JP7060503B2 (https=) |
| KR (1) | KR102736981B1 (https=) |
| CN (1) | CN108472348B (https=) |
| AU (1) | AU2016358257B2 (https=) |
| BR (2) | BR112018009753B1 (https=) |
| CA (1) | CA3003563A1 (https=) |
| CY (1) | CY1124564T1 (https=) |
| DK (1) | DK3377094T3 (https=) |
| EA (1) | EA201890868A1 (https=) |
| ES (1) | ES2880431T3 (https=) |
| HR (1) | HRP20211191T1 (https=) |
| HU (1) | HUE055132T2 (https=) |
| IL (1) | IL259052B2 (https=) |
| LT (1) | LT3377094T (https=) |
| PL (1) | PL3377094T3 (https=) |
| PT (1) | PT3377094T (https=) |
| RS (1) | RS62152B1 (https=) |
| SG (1) | SG11201803643TA (https=) |
| SI (1) | SI3377094T1 (https=) |
| SM (1) | SMT202100423T1 (https=) |
| WO (1) | WO2017085233A1 (https=) |
| ZA (1) | ZA201803902B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102648293B1 (ko) | 2014-05-21 | 2024-03-15 | 우니페르시테트 바젤 | 세균 기반 단백질 전달 |
| IL259050B2 (en) | 2015-11-19 | 2024-03-01 | Univ Basel | Bacteria-based protein delivery |
| EP3957645A1 (en) | 2016-12-20 | 2022-02-23 | Universität Basel | Virulence attenuated bacteria based protein delivery |
| KR102110993B1 (ko) * | 2018-12-20 | 2020-05-14 | 한국생명공학연구원 | 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물 |
| MX2023004760A (es) * | 2020-10-27 | 2023-07-21 | T3 Pharmaceuticals Ag | Suministro de proteinas basado en bacterias. |
| CN114712496B (zh) * | 2022-04-29 | 2023-10-13 | 中山大学·深圳 | 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用 |
| CN116064877B (zh) * | 2023-02-09 | 2024-09-20 | 宁夏大学 | 利用lamp技术快速检测阴沟肠杆菌的试剂盒及方法 |
| CN116855496B (zh) * | 2023-07-05 | 2024-08-16 | 郑州大学 | 含有干扰序列siRNA-HIF-1α的表达质粒在制备抗肝细胞癌药物中的应用 |
| WO2025037284A2 (en) * | 2023-08-17 | 2025-02-20 | Baccine Ltd. | Genetically modified bacteria for multi-modal secretion of a neoantigen |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965381A (en) | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| WO2000002996A2 (en) | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| AU2001294834A1 (en) | 2000-09-26 | 2002-04-08 | Beth Israel Deaconess Medical Center | Recombinant bcg vaccines for the prevention and treatment of cancer |
| WO2002077249A2 (en) * | 2001-03-26 | 2002-10-03 | Universite Catholique De Louvain | Type iii bacterial strains for use in medicine |
| EP1565185A4 (en) | 2002-11-07 | 2011-01-05 | Technion Res & Dev Foundation | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH |
| FR2862312B1 (fr) | 2003-11-13 | 2006-02-17 | Univ Grenoble 1 | Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas |
| EP1943344A2 (en) | 2005-10-04 | 2008-07-16 | The Ludwig Institute for Cancer Research | Methods for stimulating an immune response using bacterial antigen delivery system |
| WO2008019183A2 (en) | 2006-05-18 | 2008-02-14 | The Regents Of The University Of California | Biopolymer and protein production using type iii secretion systems of gram negative bacteria |
| TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| EP2268313A2 (en) | 2008-03-17 | 2011-01-05 | Universitätsklinikum Münster | Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| AU2012267176B2 (en) | 2011-06-08 | 2017-06-15 | Chelation Partners Incorporated | Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism |
| US9127284B2 (en) * | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
| EP3049526B1 (en) | 2013-09-24 | 2021-02-24 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| US10143743B2 (en) | 2013-11-18 | 2018-12-04 | Yale University | Non-replicating bacterial nanoparticle delivery system and methods of use |
| KR102648293B1 (ko) | 2014-05-21 | 2024-03-15 | 우니페르시테트 바젤 | 세균 기반 단백질 전달 |
| IL259050B2 (en) | 2015-11-19 | 2024-03-01 | Univ Basel | Bacteria-based protein delivery |
| EP3957645A1 (en) | 2016-12-20 | 2022-02-23 | Universität Basel | Virulence attenuated bacteria based protein delivery |
-
2016
- 2016-11-17 EP EP16797930.1A patent/EP3377094B1/en active Active
- 2016-11-17 HR HRP20211191TT patent/HRP20211191T1/hr unknown
- 2016-11-17 HU HUE16797930A patent/HUE055132T2/hu unknown
- 2016-11-17 SI SI201631290T patent/SI3377094T1/sl unknown
- 2016-11-17 EP EP21170509.0A patent/EP3903813A1/en active Pending
- 2016-11-17 BR BR112018009753-5A patent/BR112018009753B1/pt active IP Right Grant
- 2016-11-17 CA CA3003563A patent/CA3003563A1/en active Pending
- 2016-11-17 AU AU2016358257A patent/AU2016358257B2/en active Active
- 2016-11-17 JP JP2018526167A patent/JP7060503B2/ja active Active
- 2016-11-17 DK DK16797930.1T patent/DK3377094T3/da active
- 2016-11-17 LT LTEP16797930.1T patent/LT3377094T/lt unknown
- 2016-11-17 EA EA201890868A patent/EA201890868A1/ru unknown
- 2016-11-17 US US15/773,524 patent/US11166987B2/en active Active
- 2016-11-17 SG SG11201803643TA patent/SG11201803643TA/en unknown
- 2016-11-17 SM SM20210423T patent/SMT202100423T1/it unknown
- 2016-11-17 PL PL16797930T patent/PL3377094T3/pl unknown
- 2016-11-17 PT PT167979301T patent/PT3377094T/pt unknown
- 2016-11-17 BR BR122023024697-7A patent/BR122023024697A2/pt not_active Application Discontinuation
- 2016-11-17 ES ES16797930T patent/ES2880431T3/es active Active
- 2016-11-17 RS RS20210926A patent/RS62152B1/sr unknown
- 2016-11-17 CN CN201680079454.XA patent/CN108472348B/zh active Active
- 2016-11-17 KR KR1020187016568A patent/KR102736981B1/ko active Active
- 2016-11-17 WO PCT/EP2016/078084 patent/WO2017085233A1/en not_active Ceased
- 2016-11-17 IL IL259052A patent/IL259052B2/en unknown
-
2018
- 2018-06-12 ZA ZA2018/03902A patent/ZA201803902B/en unknown
-
2021
- 2021-07-22 CY CY20211100666T patent/CY1124564T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500026A5 (https=) | ||
| Ou et al. | Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application | |
| Yoon et al. | Application of genetically engineered Salmonella typhimurium for interferon-gamma–induced therapy against melanoma | |
| Aganja et al. | Salmonella as a promising curative tool against cancer | |
| EP3957644B1 (en) | Cancer immunotherapy using virus particles | |
| Shahabi et al. | Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment | |
| Thangam et al. | Advances in engineered polymer nanoparticle tracking platforms towards cancer immunotherapy—Current status and future perspectives | |
| Jellbauer et al. | CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma | |
| DK2384190T3 (en) | FORMULATIONS OF LIVELY CELLS FOR ORAL DELIVERY | |
| WO2015032165A1 (en) | Therapeutic delivery and expression system, methods and uses thereof | |
| JP2020511139A5 (https=) | ||
| Sankar | New therapeutic strategies to control and treatment of bovine mastitis | |
| US10869834B2 (en) | Treatment of inflammatory bowel disease | |
| Bergman | Anticancer vaccines | |
| Liu et al. | Engineering microorganisms for cancer immunotherapy | |
| Bergman | Cancer immunotherapy | |
| He et al. | Salmonella-based therapeutic strategies: improving tumor microenvironment and bringing new hope for cancer immunotherapy | |
| Bruno et al. | Small biological fighters against cancer: viruses, bacteria, archaea, fungi, protozoa, and microalgae | |
| Wei et al. | In situ synthesis of an immune-checkpoint blocker from engineered bacteria elicits a potent antitumor response | |
| US20240158798A1 (en) | Non-viral gene/carrier complex for prevention or treatment of acute inflammatory disease | |
| Bergman | Cancer immunotherapy | |
| Li et al. | Precision tumor immunotherapy via a dual-gated macrophage–bacterial activation platform | |
| Xu et al. | Targeting Microbe-Mediated Macrophage Education: A Novel Paradigm in Cancer Immunotherapy | |
| CN111588836B (zh) | Cd40蛋白在制备提高罗非鱼抗链球菌免疫力的制品中的应用 | |
| Zhu et al. | The treatment and prevention of mouse melanoma with an oral DNA vaccine carried by attenuated Salmonella typhimurium |